Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Constipation is reported in approximately 10-20% of patients taking GLP-1 weight loss drugs
Clinical trials are underway to try to confirm these benefits
Not all the speculation has been cautionary, of course: Morgan Stanley analysts suggest overall healthcare savings associated with GLP-1-related weight loss could top $264 billion by 2035
Lilly's phase 3 program evaluates efficacy and safety in obesity and overweight, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis pain, cardiovascular and renal outcomes, chronic low back pain, and metabolic liver disease [1]
We evaluate most patients within 2448 hours
US$ 24.91
US$ 25.85
US$ 28.04
